DC excipient

Abstract Successful development of direct-compression formulations can be hindered by poor compactibility of active pharmaceutical ingredients active pharmaceutical ingredients (APIs),...

Abstract Background/Objectives: The development of extended-release oral dosage forms remains a complicated and time consuming process, particularly during early formulation...

Abstract Minitablets are an innovative dosage form with a diameter of ≤ 3 mm that offer solutions for many unmet needs in...

Formulation Challenges in Low-Dose Fixed-Dose Combinations Developing fixed-dose combination (FDC) therapies presents unique formulation challenges, particularly when one active pharmaceutical...

Abstract Excipients are indispensable components of pharmaceutical dosage forms, significantly influencing product quality, safety, and performance. Conventional single excipients often...

Abstract Continuous Direct Compression via Mini-Batch Blending (CDC via MBB) is gaining traction as an innovative manufacturing technology in the...

Abstract In recent years, the environmental assessment and optimization of pharmaceutical dosage forms have received increasing attention. Consequently, interest in...

See the latest edition of the Fuji Chemical Technical Newsletter: THE POLYMORPHISM CHALLENGE IN BILASTINE FORMULATION Bilastine is a second-generation,...

Abstract Purposes The tabletability flip phenomenon (TFP), where an active pharmaceutical ingredient (API) with poorer tabletability exhibits better tabletability when...

See the latest edition of the Fuji Chemical Technical Newsletter: Why Etoricoxib is Difficult to Formulate? Etoricoxib, a selective COX-2...